In a recent event attended by Brazilian influencers, the Paraguayan lab Eticos announced the upcoming introduction of retatrutida-based pens intended for obesity treatment. However, regulatory authorities raised concerns since the active substance is still undergoing clinical testing and has not yet been submitted for approval by the U.S. company that holds the patent, Eli Lilly. The lack of authorization raises significant questions about the legal and ethical implications of promoting a product that is not yet commercially viable.

The event gained additional attention because it featured fitness influencer Renato Cariani, who showcased the product in promotional imagery. The announcement could mislead potential consumers about the safety and efficacy of retatrutida, given that it has not been launched nor approved for use. Furthermore, Eticos has a questionable history of promoting other medications, as seen with the Lipoless pen, which is currently banned in Brazil and has faced multiple confiscations by local authorities.

This scenario highlights the intersection between emerging health technologies and the responsibilities of pharmaceutical companies towards consumers and regulatory bodies. As social media amplifies product visibility, the potential repercussions of misleading promotions can significantly affect public health. Regulatory bodies in Brazil and Paraguay must remain vigilant in monitoring these developments and enforcing compliance to safeguard public interest.